Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrekibart in skin diseases
NCT02896868Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing LY3041658 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered Related to Study Drug. Started Nov 2016; status: completed.
02
Drugs
eltrekibart
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02896868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896868.